Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C. Becker

Showing results (41-50 of 329) with videos related to

Pageof 33
Sort By:
Current Opinion in Molecular Therapeutics|January 15, 2010
REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosisRichard C Becker, Mark Y Chan
Current Interventional Cardiology Reports|August 4, 2001
Moving Up the Coagulation Cascade: Potential Factor X Inhibition for Percutaneous Coronary InterventionRichard C. Becker, Frederick A. Spencer
Journal of Thrombosis and Thrombolysis|September 19, 2013
Emerging paradigms in arterial thrombosisJames W Wisler, Richard C Becker
Journal of Thrombosis and Thrombolysis|September 3, 2013
Structure-function relationships of factor Xa inhibitors: implications for the practicing clinicianBenjamin A Steinberg, Richard C Becker
Journal of Thrombosis and Thrombolysis|July 18, 2013
Funding opportunities for clinical investigators in the early stages of career development in cardiovascular researchRobert J Mentz, Richard C Becker
Current Opinion in Pharmacology|March 4, 2016
Reversal of novel oral anticoagulantsElsayed Abo-Salem, Richard C Becker
Journal of Thrombosis and Thrombolysis|November 19, 2009
Apixaban: an emerging oral factor Xa inhibitorChristopher Roser-Jones, Richard C Becker
Nature Reviews. Cardiology|February 22, 2012
Oral factor Xa inhibitors for the long-term management of ACSJames W Wisler, Richard C Becker
Journal of Thrombosis and Thrombolysis|August 10, 2013
Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversalLarry R Jackson, Richard C Becker
Expert Opinion on Therapeutic Targets|October 28, 2014
Antithrombotic therapy: new areas to understand efficacy and bleedingJames W Wisler, Richard C Becker
Pageof 33

Showing results (41-50 of 329) with videos related to

Sort By:
Pageof 33
Current Opinion in Molecular Therapeutics|January 15, 2010
REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosisRichard C Becker, Mark Y Chan
Current Interventional Cardiology Reports|August 4, 2001
Moving Up the Coagulation Cascade: Potential Factor X Inhibition for Percutaneous Coronary InterventionRichard C. Becker, Frederick A. Spencer
Journal of Thrombosis and Thrombolysis|September 19, 2013
Emerging paradigms in arterial thrombosisJames W Wisler, Richard C Becker
Journal of Thrombosis and Thrombolysis|September 3, 2013
Structure-function relationships of factor Xa inhibitors: implications for the practicing clinicianBenjamin A Steinberg, Richard C Becker
Journal of Thrombosis and Thrombolysis|July 18, 2013
Funding opportunities for clinical investigators in the early stages of career development in cardiovascular researchRobert J Mentz, Richard C Becker
Current Opinion in Pharmacology|March 4, 2016
Reversal of novel oral anticoagulantsElsayed Abo-Salem, Richard C Becker
Journal of Thrombosis and Thrombolysis|November 19, 2009
Apixaban: an emerging oral factor Xa inhibitorChristopher Roser-Jones, Richard C Becker
Nature Reviews. Cardiology|February 22, 2012
Oral factor Xa inhibitors for the long-term management of ACSJames W Wisler, Richard C Becker
Journal of Thrombosis and Thrombolysis|August 10, 2013
Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversalLarry R Jackson, Richard C Becker
Expert Opinion on Therapeutic Targets|October 28, 2014
Antithrombotic therapy: new areas to understand efficacy and bleedingJames W Wisler, Richard C Becker
Pageof 33